• Medientyp: E-Artikel
  • Titel: Stroma AReactive Invasion Front Areas (SARIFA)—A New Easily to Determine Biomarker in Colon Cancer—Results of a Retrospective Study
  • Beteiligte: Martin, Benedikt; Grosser, Bianca; Kempkens, Lana; Miller, Silvia; Bauer, Svenja; Dhillon, Christine; Banner, Bettina Monika; Brendel, Eva-Maria; Sipos, Éva; Vlasenko, Dmytro; Schenkirsch, Gerhard; Schiele, Stefan; Müller, Gernot; Märkl, Bruno
  • Erschienen: MDPI AG, 2021
  • Erschienen in: Cancers, 13 (2021) 19, Seite 4880
  • Sprache: Englisch
  • DOI: 10.3390/cancers13194880
  • ISSN: 2072-6694
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Many studies have used histomorphological features to more precisely predict the prognosis of patients with colon cancer, focusing on tumor budding, poorly differentiated clusters, and the tumor–stroma ratio. Here, we introduce SARIFA: Stroma AReactive Invasion Front Area(s). We defined SARIFA as the direct contact between a tumor gland/tumor cell cluster (≥5 cells) and inconspicuous surrounding adipose tissue in the invasion front. In this retrospective, single-center study, we classified 449 adipose-infiltrative adenocarcinomas (not otherwise specified) from two groups based on SARIFA and found 25% of all tumors to be SARIFA-positive. Kappa values between the two pathologists were good/very good: 0.77 and 0.87. Patients with SARIFA-positive tumors had a significantly shorter colon-cancer-specific survival (p = 0.008, group A), absence of metastasis, and overall survival (p < 0.001, p = 0.003, group B). SARIFA was significantly associated with adverse features such as pT4 stage, lymph node metastasis, tumor budding, and higher tumor grade. Moreover, SARIFA was confirmed as an independent prognostic indicator for colon-cancer-specific survival (p = 0.011, group A). SARIFA assessment was very quick (<1 min). Because of low interobserver variability and good prognostic significance, SARIFA seems to be a promising histomorphological prognostic indicator in adipose-infiltrative adenocarcinomas of the colon. Further studies should validate our results and also determine whether SARIFA is a universal prognostic indicator in solid cancers.
  • Zugangsstatus: Freier Zugang